Compare Amylx Pharmaceuticals Inc (AMLX) vs Conagra Brands Inc (CAG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Conagra Brands Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Conagra Brands Inc trades at $13.89 (market cap $6.62B). The key difference: Conagra Brands Inc is far larger — about 3.3× Amylx Pharmaceuticals Inc's market cap, and Conagra Brands Inc pays a 10.12% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | CAG | |
|---|---|---|
Market Cap | $1.98B | $6.62B |
Sector | Health | Consumer Staples |
52-Week High | $18.70 | $20.02 |
52-Week Low | $7.64 | $12.58 |
Enterprise Value | $1.70B | $13.89B |
Dividend Yield | — | 10.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Conagra Brands (CAG) trades at $13.83, up 3.52% today but remains near its 52-week lows with a bearish technical outlook. The stock shows mixed fundamentals with a negative net income margin of -0.39% despite recent revenue stabilization around $11.6B. Analyst sentiment is cautious with 62.5% hold ratings, while recent news highlights concerns about dividend sustainability given the company's 10%+ yield and elevated debt levels.
CAG presents a high-risk opportunity with its deeply discounted valuation (P/E 10.06, P/B 0.81) and substantial dividend yield, but faces significant headwinds including declining earnings, high leverage, and competitive pressures in the consumer staples sector. The upcoming Q2 2026 earnings report on July 15 will be critical for confirming operational turnaround prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Conagra Brands Inc
Conagra Brands is a packaged food company that operates predominantly in the United States (over 90% of revenue and profits). It has a significant presence in the freezer aisle, with brands such as Marie Callender's, Healthy Choice, Banquet, and Birds Eye. Other popular brands include Duncan Hines, Hunt's, Slim Jim, Vlasic, Orville Redenbacher's, Reddi-wip, Wish-Bone, and Chef Boyardee. While the majority of revenue is sold into the U.S. retail channel, 9% of fiscal 2022 sales were to the food-service channel, down from 11% in fiscal 2019 due to the pandemic.
Read more on CAG →
